Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon Pockets $5.7M in Series A Financing Round

NEW YORK, Aug. 26 - Synthetic RNA developer Dharmacon Research has secured $5.7 million in a Series A round of private-equity financing.


Boulder Ventures led the round, which included investments by Telegraph Hill Partners.


The company, based in Lafayette, Colo., said it will use the cash to bolster R&D and automation.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.